1 / 6

Peptic Ulcer Disease

Peptic Ulcer Disease. Lerma , Daniel Joseph M. Peptic Ulcer Disease. Ulcer - disruption of the mucosal integrity of the stomach and/or duodenum leading to a local defect or excavation due to active inflammation; breaks in the mucosal surface >5 mm in size, with depth to the submucosa .

kimball
Télécharger la présentation

Peptic Ulcer Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Peptic Ulcer Disease Lerma, Daniel Joseph M.

  2. Peptic Ulcer Disease • Ulcer - disruption of the mucosal integrity of the stomach and/or duodenum leading to a local defect or excavation due to active inflammation; breaks in the mucosal surface >5 mm in size, with depth to the submucosa. • Burning epigastric pain exacerbated by fasting and improved with meals is a symptom complex associated with PUD

  3. Epidemiology/Incidence • Duodenal Ulcer • occur in 6–15% of the Western population • incidence of DUs declined steadily from 1960 to 1980 and has remained stable since then • death rates, need for surgery, and physician visits have decreased by >50% over the past 30 years; reason for the reduction in the frequency of DUs is likely related to the decreasing frequency of Helicobacter pylori. • Gastric Ulcer • tend to occur later in life than duodenal lesions, peak incidence in 6th decade of life • More than half occur in males; higher likelihood of being “silent” and presenting only after a complication develops

  4. Pathology • Duodenal Ulcer • occur first portion of duodenum (>95%), with ~90% located within 3 cm of the pylorus. • usually 1 cm in diameter; can reach 3–6 cm (giant ulcer). • sharply demarcated, sometimesreaching the muscularispropria; base of the ulcer often consists of a zone of eosinophilic necrosis with surrounding fibrosis. Malignant DUs are extremely rare. • Gastric Ulcer • In contrast to DUs, GUs can represent a malignancy • Benign GUs  often found distal to the junction between the antrum and the acid secretory mucosa; quite rare in the gastric fundus and are histologically similar to DUs. • Benign GUs associated with H. pylori are also associated with antral gastritis

  5. UGI Bleeding due to PUD • Peptic ulcers are the most common cause of UGIB (50% of cases) • increasing proportion is due to NSAIDs, with the prevalence of H. pylori decreasing. • Ulcer characteristics at endoscopy provide important prognostic information. • 1/3 of patients with active bleeding or a nonbleeding visible vessel have further bleeding that requires urgent surgery if they are treated conservatively.* • In contrast, patients with clean-based ulcers have rates of recurrent bleeding approaching zero. **

  6. One-third of patients with a bleeding ulcer will rebleed within the next 1–2 years. Prevention of recurrent bleeding focuses on the three main factors in ulcer pathogenesis • H. pylori eradication • NSAIDs should be discontinued if a bleeding ulcer develops, and if NSAIDs must be continued, initial treatment should be with a PPI. Long-term preventive strategies to decrease NSAID-associated ulcers include use of a cyclooxygenase 2 (COX-2) selective inhibitor (coxib) or addition of GI co-therapy to a traditional NSAID • Patients with bleeding ulcers unrelated to H. pylori or NSAIDs should remain on full-dose antisecretory therapy indefinitely. Peptic ulcers are discussed in Chap. 287.

More Related